Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT03965689 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05215548 | Primary Tumor Resection With EGFR TKI for Stage IV NSCLC | recruiting | Phase 2 | 100 | National Taiwan University HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05696782 | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | recruiting | Phase 2 | 28 | Wake Forest University Health SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07104630 | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors | recruiting | Phase 2 | 85 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01350817 | Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer(TARSEQ) | completed | Phase 2 | 156 | University Hospital, LimogesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04216316 | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT06114511 | A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 78 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06745882 | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | recruiting | Phase 2 | 318 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT03410043 | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | active not recruiting | Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04105270 | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | recruiting | Phase 2 | 82 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT07084610 | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.(TeLuRide-008) | recruiting | Phase 2 / Phase 3 | 750 | Eikon TherapeuticsINDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824882 | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 2 | 76 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT01629498 | Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 146 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03831932 | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Regeneron PharmaceuticalsINDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT04486833 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib(Acclaim-1) | recruiting | Phase 1 / Phase 2 | 158 | Genprex, Inc.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05208944 | THIO Sequenced With Cemiplimab in Advanced NSCLC | active not recruiting | Phase 2 | 227 | Maia BiotechnologyINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06008730 | Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer | recruiting | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07323732 | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07806773 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 80 | Tubulis GmbHINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822984 | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy | not yet recruiting | Phase 2 | 374 | Fudan UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04969315 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | recruiting | Phase 1 / Phase 2 | 35 | Portage BiotechINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07132918 | HEARTS Trial for Thoracic Cancers | recruiting | Phase 2 | 60 | University of Wisconsin, MadisonOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials